Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial.
Pieter C SmitsEnrico FrigoliJan TijssenPeter JüniPascal VranckxYukio OzakiMarie-Claude MoriceBernard ChevalierYoshinobu OnumaStephan WindeckerPim A L ToninoMarco RoffiMaciej LesiakFelix MahfoudJozef BartunekDavid Hildick-SmithAntonio ColomboGoran StankovicAndrés IñiguezCarl Johann SchultzRan KornowskiPaul Jau Lueng OngMirvat AlasnagAlfredo E RodriguezAris MoschovitisPeep LaanmetsDik HegMarco Valgimiglinull nullPublished in: Circulation (2021)
Rates of net adverse clinical outcomes and major adverse cardiac and cerebral events did not differ with abbreviated APT in patients with high bleeding risk with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03023020.
Keyphrases
- antiplatelet therapy
- atrial fibrillation
- randomized controlled trial
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- newly diagnosed
- coronary artery disease
- coronary artery
- prognostic factors
- study protocol
- peritoneal dialysis
- venous thromboembolism
- left ventricular
- emergency department
- subarachnoid hemorrhage
- aortic stenosis
- transcatheter aortic valve replacement
- patient reported
- blood brain barrier